March 22, 2012 – St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the worldwide launch of its EnSite™ Velocity™ System Version 3.0 software. The new benefits of this software release are designed to help shorten procedure times for patients undergoing electrophysiology (EP) procedures guided by a cardiac mapping system and improve workflow efficiencies in the EP lab.
A new feature in the EnSite Velocity System is the OneModel™ tool, which can increase the physician’s confidence in anatomic and electrical mapping data by creating a highly detailed and precise model of a patient’s cardiac anatomy. Initial clinical experience with the OneModel tool has demonstrated a 54 percent reduction in cardiac model creation time while significantly improving dimensional accuracy, resulting in an image comparable to a CT scan.
“The EnSite Velocity System has always been able to create detailed chamber models; however, the OneModel tool provides even more detail in significantly less time,” said Dr. Larry Chinitz, director of clinical cardiac electrophysiology at New York University Langone Medical Center. “The greater level of anatomic detail and resulting reduction of discrepancies in the anatomic model will help drive better procedural success rates with fewer complications. It is possible that for some patients, a pre-procedure CT or MRI scan may not be needed to guide cardiac mapping system procedures.”
Another enhancement designed to increase procedural efficiency is the Adaptive Respiration Compensation feature, which automatically compensates for changes in patient respiration patterns throughout an entire procedure.
The EnSite Velocity System is used in minimally invasive electrophysiology procedures. Catheters with electrodes are inserted into a cardiac chamber; these electrodes are then located or visualized by the system, which records electrical information from the heart and displays it in a three-dimensional anatomical model. The highly detailed anatomical models, or maps, enable physicians to diagnose and guide therapy for abnormal heart rhythms. The EnSite Velocity System is an open platform and is the only cardiac mapping system that supports the translation of the user interface into eight non-English languages.
"The enhancements delivered in the EnSite Velocity System v.3.0 software further establish the EnSite Velocity System as the premier cardiac mapping system," said Jane J. Song, president of the St. Jude Medical Atrial Fibrillation Division. "St. Jude Medical is committed to offering physicians efficient and effective tools that help deliver curative solutions to improve patients’ lives.”
About St. Jude Medical
St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. St. Jude Medical is headquartered in St. Paul, Minn. and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.